UCB’s Bets on Complement Diseases with US$2.1 B Ra Pharma Acquisition
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 10 (Table of Contents)
Published: 15 Oct-2019
DOI: 10.3833/pdr.v2019.i10.2461 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
UCB has agreed to acquire Ra Pharmaceuticals (Ra Pharma), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases of the complement system...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS